Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
| Catalog No. | Product Name | Size | List Price (US$) | Quantity |
|---|
Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use.
Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
Background Information:
B-cell antigen receptor (BCR) signaling is required for tumor expansion and proliferation. Bruton's Tyrosine Kinase (BTK) is an essential element of the BCR signaling pathway, playing an important role in B lymphocyte development, activation, signaling, proliferation and survival. Inhibiting BTK blocks BCR signaling and is of therapeutic significance in the treatment of both of B cell-related hematological cancers (e.g. non-Hodgkin lymphoma (NHL) and B cell chronic lymphocytic leukemia (B-CLL), and autoimmune diseases (e.g. rheumatoid arthritis). AVL-292 is a potent, selective and orally bioavailable irreversible inhibitor of BTK with IC50 value at low nM, currently in clinical trials.
Reference:
1. Robak T, et al, Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders. Expert Opin Investig Drugs. 2012 Jul;21(7):921-47.
APIM050012: AVL-292 (SPEBRUTINIB)
CAS No.: 1202757-89-8.
Molecular Formula: C22H22FN5O3.
Molecular Weight: 423.
Purity: >98.5% by HPLC.
QC: HPLC-MS, 1HNMR, and Quantitative Elemental Analysis.
Solubility: Soluble in DMSO.
Storage: Store at 0°C (short term), -20°C (long term), desiccated.
Copyright © 2009-2022 sydlabs.com. All rights reserved.
Use of this website means that you have read, understood, and accepted the Syd Labs Privacy Policy and Terms & Conditions.